Clinical Trial Update: Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab as neoadjuvant therapy for non-resectable colorectal liver metastases; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer with Liver Metastases

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Colorectal Cancer, Liver Metastases | Phase 2 | Status: COMPLETED